Flagging notification

ODI Pharma AB ("ODI Pharma") hereby informs that the current CEO, Derek Simmross, did not subscribe to his pro-rata in the completed rights issue in ODI Pharma and has therefore fallen below the threshold of 25 percent.  

Derek Simmross has fallen below the flagging threshold of 25 percent through the rights issue. Derek Simmross's total shareholding before the transaction amounted to 3,950,000 shares, equivalent to approximately 25.95% of the voting and capital share. After the transaction, Derek’s holdings amount to the same amount of shares, 3,950,000, however equivalent to approximately 24,82% of the voting and capital share in the company.

For more information on ODI Pharma, please contact:

Volker Wiederrich, Chairman, ODI Pharma AB

E-mail: info@odipharma.com  

ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.